Synthesis of Novel 3-Aryl-N-Methyl-1,2,5,6-Tetrahydropyridine Derivatives by Suzuki coupling: As Acetyl Cholinesterase Inhibitors

Alzheimer’s disease (AD) is a neurodegenerative disorder affecting the central nervous system, which is also associated with progressive loss of memory and cognition. The development of numerous structural classes of compounds with different pharmacological profile could be an evolving, promising therapeutic approach for the treatment of AD. Thus, providing a symptomatic treatment for this disease are cholinomimetics with the pharmacological profile of Acetylcholinesterase (AChE) inhibitors. In view of this, we have synthesized novel 3-aryl-N-methyl-1,2,5,6-tetrahydropyridine derivatives 5a-k by Suzuki coupling and screened the efficacy of these derivatives for their AChE inhibitor activity

Synthesis and evaluation of 1-benzhydryl-sulfonyl-piperazine derivatives as inhibitors of MDA-MB-231 human breast cancer cell proliferation

10.1007/s00044-007-9022-yMedicinal Chemistry Research164179-187MCRE

Synthesis, antimicrobial activity and molecular docking studies of novel hydantoin derivatives as potential phospholipase A2 inhibitors

This work presents the synthesis, characterization and evaluation of a series of new multifunctional N-substituted hydantoin derivatives for their antibacterial and antifungal activity. Elemental analysis, 1H NMR, 13C NMR, and mass spectroscopy were used to confirm the newly synthesized compounds' structure. The antibacterial and antifungal properties of each synthesized molecule were examined. The examined compounds showed significant to moderate antimicrobial activity against the tested Gram-positive, Gram-negative, and fungal strains with MIC values ranging from 10.3 to 84.2 µM. Compounds 22 (MIC: 11.7–13.5 µM) and 25 (MIC: 10.2–11.9 µM) demonstrated an impressive MIC value against the tested bacterial and fungal strains when compared to the reference medications fluconazole (MIC: 11.7–14.5 µM) and streptomycin (MIC: 14.5 µM), which are broad-spectrum antibiotics and antifungal agents, respectively. Additionally, all of the compounds were tested for their ability to inhibit the phospholipase A2 (PLA2) enzyme, with the IC50 values ranging from 8.53 to 65.14 µM. When compared to the reference drug ursolic acid (IC50: 12.58 µM), compounds 22 (IC50: 10.27 µM) and 25 (IC50: 8.53 µM) were shown to be the most potent PLA2 inhibiting compounds in this series. The findings of the Molecule description with Drug-Likeness Prediction demonstrated that all the compounds are in a linear correlation with Lipinski's rule of five, demonstrating good drug-likeness qualities. The inhibitory effects of the most potent compounds (18, 19, 22 and 25) against the target PLA2 protein (PDB ID: 2H4C) were explained by molecular docking studies. The molecular docking results were in good accord with the experimental findings, and as these compounds had superior binding affinities within the active pocket, they may be classified as potent inhibitors of specific targets